Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Colorectal Neoplasms 73Colonic Neoplasms 14Rectal Neoplasms 13Neoplasm Metastasis 12Stomach Neoplasms 8Pancreatic Neoplasms 5Advanced Solid Tumors 5Neoplasms 4Colorectal Cancer Metastatic 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma 3Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Colorectal Cancer 2Adenocarcinoma Of Esophagus 2mCRC 1Urologic Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Solid Tumor 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Advanced Solid Tumors × trifluridine tipiracil drug combination × Clear all
NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04626635 2026-04-09

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
933 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04393298 2025-05-29

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

UCB Pharma

Phase 1/2 Completed
93 enrolled 28 charts
Other solid neoplasm

Advanced Solid Tumors

NCT01867866 2024-09-05

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT02031055 2024-09-05

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
8 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡